CLDN6-CAR NK-92MI cells

CLDN6-CAR NK-92MI cells are genetically engineered cell therapy products derived from the NK-92MI natural killer cell line, which express a chimeric antigen receptor (CAR) targeting **Claudin-6 (CLDN6)**, a tight junction protein highly and selectively expressed on the surface of certain solid tumors, notably ovarian cancer cells, but not on most normal adult tissues. Two main third-generation CAR constructs have been described: one based on activating NK cell signaling domains (NKG2D, 2B4) and another using classical T cell domains (CD28, 4-1BB). The CAR-modified cells demonstrate potent and selective cytotoxic activity against CLDN6-positive tumor cells, enhanced cytokine secretion (TNF-α, IFN-γ, GM-CSF, perforin, granzyme B), and improved antitumor effects in preclinical in vitro and in vivo models of ovarian cancer. Additional antitumor synergy was seen when CLDN6-CAR NK-92MI cells were combined with immune checkpoint blockade (e.g., anti-PD-L1 antibody). This approach represents a promising modality for immunotherapy of CLDN6-positive malignancies, with the primary indication in preclinical development being ovarian cancer[1][2][3].

Other names

claudin-6 CAR NK-92MI cellsclaudin6 CAR NK-92MI cellsclaudin 6 CAR NK-92MI cellsanti-CLDN6 CAR NK-92MI cellsanti-CLDN-6 CAR NK-92MI cellsanti-CLDN 6 CAR NK-92MI cellsCLDN6-CAR NK cellsCLDN-6-CAR NK cellsCLDN 6-CAR NK cells